Akciju sabiedr\u012bba Grindeks akt\u012bvo farmaceitisko vielu (AFV) ra\u017eotn\u0113 ir invest\u0113jusi 800 t\u016bksto\u0161us eiro un uzst\u0101d\u012bjusi jaunas, m\u016bsdien\u012bgas laboratorijas un r\u016bpniecisk\u0101s ra\u017eo\u0161anas tehnolo\u0123isk\u0101s iek\u0101rtas, kas iecirknim \u013c\u0101vis k\u013c\u016bt multifunkcion\u0101lam.<\/p>\n\n\n\n
P\u0113c veiktaj\u0101m invest\u012bcij\u0101m iecirkni var\u0113s izmantot gan jaunu akt\u012bvo farmaceitisko vielu AFV izstr\u0101des procesiem, gan \u0161o vielu ra\u017eo\u0161anai sav\u0101m vajadz\u012bb\u0101m \u2013 gatavo z\u0101\u013cu ra\u017eo\u0161anai, k\u0101 ar\u012b eksportam. Iecirkn\u012b ir iesp\u0113ja str\u0101d\u0101t ar iek\u0101rt\u0101m, kuru tilpums ir no 100ml l\u012bdz 20l, kas at\u013cauj ra\u017eot da\u017e\u0101das akt\u012bv\u0101s vielas no miligramiem l\u012bdz pat kilogramiem.<\/p>\n\n\n\n
Lai r\u016bp\u0113tos par darbinieku dro\u0161\u012bbu un vides aizsardz\u012bbu, uzst\u0101d\u012bts ra\u017eo\u0161anas specifikai atbilsto\u0161s pazemin\u0101ta spiediena izolators ar filtr\u0113\u0161anas sist\u0113m\u0101m, kas ne\u013cauj augsti efekt\u012bv\u0101m AFV nok\u013c\u016bt saskar\u0113 ar cilv\u0113kiem un apk\u0101rt\u0113jo vidi. \u0160\u012b ir pirm\u0101 \u0161\u0101da veida iek\u0101rta Grindeks AFV ra\u017eotn\u0113. Telp\u0101 uzst\u0101d\u012bta ar\u012b m\u016bsdien\u012bga uzraudz\u012bbas un komunik\u0101cijas sist\u0113ma \u0101trai rea\u0123\u0113\u0161anai nestandarta situ\u0101ciju gad\u012bjum\u0101.<\/p>\n\n\n\n
Grindeks padomes priek\u0161s\u0113d\u0113t\u0101js Kirovs Lipmans: \u201cLai Grindeks koncerns sp\u0113tu strauji augt, ir nepiecie\u0161amas invest\u012bcijas ra\u017eo\u0161anas att\u012bst\u012bb\u0101. Ik gadu m\u0113s att\u012bst\u012bb\u0101 invest\u0113jam vismaz 10 milj. eiro, un tas ir garants ilgtsp\u0113j\u012bgai koncerna n\u0101kotnei. \u0160\u0101di farm\u0101cijas industrija Latvij\u0101 nostiprin\u0101s, sp\u0113c\u012bgi piesaka sevi glob\u0101l\u0101 ar\u0113n\u0101 un dod pienesumu Latvijas ekonomikai.\u201d<\/p>\n\n\n\n
AS Grindeks valdes priek\u0161s\u0113d\u0113t\u0101js Dr. chem. Juris Hme\u013c\u0146ickis:\u201cAkt\u012bvo farmaceitisko vielu p\u0113tniec\u012bba, izstr\u0101de, ra\u017eo\u0161ana un p\u0101rdo\u0161ana ir viens no m\u016bsu biznesa virzieniem. M\u0113s ra\u017eojom produktus ar augstu pievienoto v\u0113rt\u012bbu, un tiem ir milz\u012bgs eksporta potenci\u0101ls. Pateicoties jaun\u0101 iecirk\u0146a multifunkcionalit\u0101tei, izstr\u0101des un ra\u017eo\u0161anas procesus var\u0113sim organiz\u0113t \u0113rt\u0101k un produkt\u012bv\u0101k. Savienojot daudzu gadu pieredzi farm\u0101cij\u0101, profesion\u0101lo kompetenci un m\u016bsdien\u012bg\u0101s tehnolo\u0123ijas, pacientiem b\u016bs pieejami efekt\u012bvi medikamenti.\u201d<\/p>\n\n\n\n
Paredz\u0113ts, ka \u0161aj\u0101 multifunkcion\u0101laj\u0101 iecirkn\u012b tiks ra\u017eotas AFV, kuras p\u0113c\u0101k izmantos prets\u0101pju medikamentu, musku\u013cu relaksantu un kardiovaskul\u0101ro prepar\u0101tu ra\u017eo\u0161anai. \u0160\u012bs z\u0101les papla\u0161in\u0101s Grindeks meitas uz\u0146\u0113muma Kalceks medikamentu kl\u0101stu, kas paredz\u0113ts slimn\u012bcu vajadz\u012bb\u0101m.<\/p>\n\n\n\n
Grindeks produktu kl\u0101st\u0101 ir m\u016bsdien\u012bgi medikamenti sirds un asinsvadu, centr\u0101l\u0101s nervu sist\u0113mas, onkolo\u0123isko saslim\u0161anu un diab\u0113ta \u0101rst\u0113\u0161anai, savuk\u0101rt meitas uz\u0146\u0113rmums \u201cKalceks\u201d pied\u0101v\u0101 medikamentus slimn\u012bcu segmentam. Izstr\u0101d\u0113 \u0161obr\u012bd ir 63 jauni Grindeks un 42 jauni Kalceks medikamenti.<\/p>\n\n\n\n
AFV ra\u017eo\u0161ana Grindeks koncernam ir \u013coti noz\u012bm\u012bga un t\u0101 ir viena no koncerna b\u016btiskaj\u0101m priek\u0161roc\u012bb\u0101m farm\u0101cijas nozar\u0113, kas palielina neatkar\u012bbu no izejvielu ra\u017eot\u0101jiem. Pa\u0161reiz uz\u0146\u0113mums ra\u017eo 25 AFV. Da\u017e\u0101d\u0101s izstr\u0101des stadij\u0101s ir 26 AFV. Liel\u0101kais Grindeks AFV eksports tiek veikts uz Eiropas Savien\u012bbas valst\u012bm, ASV, Jap\u0101nu un Kan\u0101du.<\/p>\n\n\n\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
Akciju sabiedr\u012bba Grindeks akt\u012bvo farmaceitisko vielu (AFV) ra\u017eotn\u0113 ir invest\u0113jusi 800 t\u016bksto\u0161us eiro un uzst\u0101d\u012bjusi jaunas, m\u016bsdien\u012bgas laboratorijas un r\u016bpniecisk\u0101s ra\u017eo\u0161anas tehnolo\u0123isk\u0101s iek\u0101rtas, kas iecirknim…<\/p>\n","protected":false},"author":3,"featured_media":3264,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-3267","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunums"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/3267","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=3267"}],"version-history":[{"count":0,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/3267\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/3264"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=3267"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=3267"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=3267"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}